Get Task & Purpose in your inbox
VA to offer new ketamine-based nasal spray to help combat depression
The newest FDA-approved medication to treat severe depression, a nasal spray based on the anesthetic (and misused hallucinogenic party drug) ketamine, will soon be available to veterans treated within the Department of Veterans Affairs.
In a move that may help thousands of former service members with depression that has not improved with other treatments, VA officials announced Tuesday that the department's doctors are now authorized to prescribe Spravato, the brand name for esketamine, a molecular variation of ketamine.
The decision to offer a drug hailed by many as a breakthrough in treatment for its speedy results -- often relieving symptoms in hours and days, not weeks -- shows the VA's "commitment to seek new ways to provide the best health care available for our nation's veterans," Secretary Robert Wilkie said in a release.
"We're pleased to be able to expand options for Veterans with depression who have not responded to other treatments," Wilkie added.
The treatment will be available to veterans based on a physician's assessment and only will be administered to patients who have tried at least two antidepressant medications and continue to have symptoms of major depressive disorder.
An estimated 16 million Americans have had at least one major episode of depression, and of those, 1 in 3 are considered treatment-resistant. In the veteran population of 20 million, the estimated diagnosis rate of depression is 14 percent -- up to 2.8 million veterans. Between one-third and half of those veterans may be treatment-resistant.
The lack of effective medications for difficult-to-treat patients prompted the Food and Drug Administration to place esketamine on a fast track, expediting its review of the drug to ensure that it went to patent as soon as safely possible, according to administration officials.
"Controlled clinical trials that studied the safety and efficacy of this drug, along with careful review through the FDA's drug approval process, including a robust discussion with our external advisory committees, were important in our decision to approve this treatment," said Dr. Tiffany Farchione, acting director of the FDA's Center for Drug Evaluation and Research Division of Psychiatry Products, in a release.
As with any other medication, there are risks. Spravato carries a boxed warning for side effects that include misuse, the reason it is administered under a doctor's supervision. The list of side effects includes sedation and blood pressure spikes and disassociation, such as feelings of physical paralysis and out-of-body experiences. It also can cause suicidal thoughts and behaviors.
Acknowledging the dangers, FDA made esketamine available only through a restricted distribution system.
A veteran prescribed Spravato would inhale the nasal spray at a medical facility while under supervision of a medical provider, and would be monitored for at least two hours after receiving the dose. A typical prescription includes twice-weekly doses the first month, followed by a single dose weekly or biweekly as needed. Spravato cannot be dispensed for home use.
Spravato is made by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It is the first major antidepressant medication to hit the market in 30 years.
This article originally appeared on Military.com
More articles from Military.com:
- Army Launches New App to Help Reservists Find Each Other
- Air Force Requests Billions to Modernize Crumbling Base Infrastructure
- Army Official Previews Timelines for Next-Gen Vehicles, Aircraft
Kade Kurita, the 20-year-old West Point cadet who had been missing since Friday evening, was found dead on Tuesday night, the U.S. Military Academy announced early Wednesday morning.
"We are grieving this loss and our thoughts and prayers go out to Cadet Kurita's family and friends," Lt. Gen. Darryl Williams, superintendent of West Point, said in the release.
The Air Force is investigating whether an airman smoked weed at a missile alert facility for nuclear Minuteman ICBMs
The Air Force is investigating reports that an airman consumed marijuana while assigned to one of the highly-sensitive missile alert facility (MAF) responsible for overseeing 400 nuclear GM-30G Minuteman III intercontinental ballistic missiles at Minot Air Force Base in North Dakota.
Mark Mitchell is stepping down as the acting assistant defense secretary for special operations and low-intensity conflict, a position he has held since late June, a defense official confirmed on Tuesday.
No information was immediately available about why Mitchell decided to resign. His last day will be Nov. 1 and he will be replaced by Thomas Alexander, who is currently leading the Defense Department's counternarcotics efforts, the defense official told Task & Purpose.
The U.S. Army's Next Generation Squad Weapon effort looked a lot more possible this week as the three competing weapons firms displayed their prototype 6.8mm rifles and automatic rifles at the 2019 Association of the United States Army's annual meeting.
Just two months ago, the Army selected General Dynamics Ordnance and Tactical Systems inc., Textron Systems and Sig Sauer Inc. for the final phase of the NGSW effort — one of the service's top modernization priorities to replace the 5.56mm M4A1 carbine and the M249 squad automatic weapon in infantry and other close-combat units.
Army officials, as well as the companies in competition, have been guarded about specific details, but the end result will equip combat squads with weapons that fire a specially designed 6.8mm projectile, capable of penetrating enemy body armor at ranges well beyond the current M855A1 5.56mm round.
There have previously been glimpses of weapons from two firms, but this year's AUSA was the first time all three competitors displayed their prototype weapons, which are distinctly different from one another.
We salute the Marine scout sniper who snuck up on an enemy completely naked except for a pair of boots
An expert sniper can sneak up on an enemy naked as the day he was born. It's not particularly advised, but one top sharpshooter did exactly that just to prove a point, Marine snipers told Insider.